Carter Gould
Stock Analyst at Barclays
(0)
# 3309
Out of 5,218 analysts
211
Total ratings
43.86%
Success rate
3.42%
Average return
Main Sectors:
| Name | Action | Price Target | Current | % Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
Gilead Sciences | Maintains: Equal-Weight | 84 95 | 91.85 | 3.43% | 14 | Nov 7, 2024 | |
Regeneron Pharmaceut... | Maintains: Overweight | 1080 1065 | 730.7 | 45.75% | 18 | Nov 1, 2024 | |
Travere Therapeutics | Maintains: Overweight | 18 20 | 17.3 | 15.61% | 6 | Nov 1, 2024 | |
Eli Lilly | Maintains: Overweight | 1025 975 | 789.07 | 23.56% | 11 | Oct 31, 2024 | |
Biogen | Maintains: Equal-Weight | 190 180 | 150.04 | 19.97% | 24 | Oct 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 42 43 | 55.73 | -22.84% | 14 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 142 140 | 102.09 | 37.13% | 10 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 300 315 | 270.45 | 16.47% | 16 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 200 212 | 173.5 | 22.19% | 14 | Oct 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 180 160 | 126.68 | 26.3% | 11 | Sep 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 100 | 86.68 | 15.37% | 1 | Aug 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 10 3 | 0.98 | 206.12% | 4 | Aug 14, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 30 32 | 25.59 | 25.05% | 14 | Jul 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 7 3 | 0.91 | 229.67% | 1 | Jun 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Initiates Coverage On: Overweight | 9 | 3.86 | 133.16% | 1 | Jun 11, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 100 95 | 48.66 | 95.23% | 2 | May 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 25 20 | 17.98 | 11.23% | 5 | Apr 16, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 62 73 | 83.86 | -12.95% | 4 | Feb 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Underweight | 2 1 | 1.04 | -3.85% | 4 | Jan 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 110 172 | n/a | n/a | 7 | Aug 1, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 14 12 | 1.98 | 506.06% | 4 | May 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 2 2 | 0.92 | 63.04% | 6 | Mar 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Overweight | 68 15 | 0.4 | 3650% | 3 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 3 3 | 1.15 | 95.65% | 4 | Aug 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Equal-Weight | 392 380 | 234.5 | 62.05% | 1 | Jan 20, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Equal-Weight | 150 180 | n/a | n/a | 4 | Oct 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | n/a | n/a | n/a | 4 | Apr 1, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Downgrades: Neutral | 75 82 | 68.61 | 19.52% | 3 | Jan 16, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade
| Maintains: Neutral | 183 188 | 463.5 | -59.44% | 1 | Jul 26, 2018 |